Skip to search formSkip to main contentSkip to account menu

PIXY321 fusion protein, recombinant

Known as: PIXY321, PIXY321 protein, recombinant, pIXY 321 protein, recombinant 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (4)

Granulocyte-Macrophage Colony-Stimulating FactorInterleukin-3Recombinant Fusion Proteinsmilodistim

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Colour tracking technique by using pixy CMUcam5 for wheelchair luggage follower
Wheelchair user will face various challenges during travelling from one destination to another. Their hands will be required to… 
1998
1998
Phase I/II trial of PIXY321 (granulocyte‐macrophage colony stimulating factor/interleukin‐3 fusion protein) for treatment of inherited and acquired marrow failure syndromes
Fourteen paediatric patients with advanced amegakaryocytic thrombocytopenia (AMT) or other bone marrow (BM) failure syndromes… 
1997
1997
Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's…
PURPOSE A phase III trial to compare PIXY321 with granulocyte-macrophage colony-stimulating factor (GM-CSF) following high-dose… 
1996
1996
Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells.
PURPOSE Mobilization of peripheral-blood cells (PBC) with cytokines alone results in rapid hematopoietic recovery and avoids the… 
1996
1996
Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy.
PURPOSE A phase I/II study of PIXY321 following high-dose therapy (HDT) and autologous bone marrow transplantation (ABMT) was… 
1996
1996
Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer.
1996
1996
The effect of the GM‐CSF/IL‐3 fusion protein PIXY321 on bone marrow and circulating haemopoietic cells of previously untreated patients with cancer
This is a phase I/II study of the GM‐CSF/IL‐3 fusion protein PIXY321. Patients were treated with PIXY321 at a daily subcutaneous… 
1995
1995
Effects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma.
PIXY321, a stimulator of multipotent colony-forming units (CFU-GEMM), burst-forming unit-erythroid (BFU-E), and colony-forming… 
1995
1995
pIXY321 protects against Ara-C or taxol-induced apoptosis and loss of clonogenic survival of normal human bone marrow progenitor cells.
By suppressing apoptosis, hemopoietic growth factors (HGFs) promote the survival of CD34+, HLA-DR+ marrow cells that are enriched… 
1992
1992
The In Vitro Effects of Stem Cell Factor and PIXY321 on Myeloid Progenitor Formation (CFU-GM) from Immunomagnetic Separated CD34+ Cord Blood
ABSTRACT: Two novel cytokines, stem cell factor (SCF) and PIXY321 (a fusion protein, granulocyte macrophage colony-stimulating… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)